Phospholipase C β4 promotes RANKL-dependent osteoclastogenesis by interacting with MKK3 and p38 MAPK

Area of Science:

• Cell Biology
• Bone Biology
• Biochemistry

Background:

• Phospholipase C beta (PLCβ) isoforms regulate various cellular processes.
• The role of PLCβ in bone cell function, particularly osteoclastogenesis, remains largely unexplored.
• PLCβ4 is identified as the most upregulated isoform during osteoclast differentiation.

Purpose of the Study:

• To investigate the role of PLCβ4 in osteoclast differentiation and bone metabolism.
• To elucidate the molecular mechanism by which PLCβ4 regulates osteoclastogenesis.
• To assess the potential of PLCβ4 as a therapeutic target for bone diseases.

Main Methods:

• Utilized global and osteoclast lineage-specific PLCβ4 conditional knockout mice (LysM-PLCβ4^-/-).
• Analyzed osteoclast formation, osteoclast marker gene expression, and bone mass in vivo.
• Investigated protein-protein interactions and signaling pathways using co-immunoprecipitation and Western blotting.

Main Results:

• PLCβ4 deficiency significantly reduced osteoclast formation and downregulated osteoclast marker genes.
• Male LysM-PLCβ4^-/- mice exhibited increased bone mass and reduced osteoclast numbers without affecting osteoblast function.
• PLCβ4 interacts with MKK3 and p38 MAPK, modulating p38 activation in response to RANKL.

Conclusions:

• PLCβ4 is a critical regulator of RANKL-induced osteoclast differentiation via the MKK3-p38 MAPK pathway.
• Targeting PLCβ4 may offer a novel therapeutic strategy for bone diseases like osteoporosis.
• This study reveals a novel signaling axis controlling bone resorption.